Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04988308 · ClinicalTrials.gov registry record · Phase 2
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 2 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT04988308 is a Phase 2 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 151 participants.
The verdict
NCT04988308, a Phase 2 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the clinical efficacy of bermekimab in participants with moderate to severe Hidradenitis Suppurativa (HS).
Interventions
- DRUG Placebo
- DRUG Adalimumab
- DRUG Bermekimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2021-10-12 |
| Est. Completion | 2022-11-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04988308
The ClinicalTrials.gov registry entry for NCT04988308 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04988308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04988308 about?
NCT04988308 is a clinical study titled "A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa". The purpose of this study is to evaluate the clinical efficacy of bermekimab in participants with moderate to severe Hidradenitis Suppurativa (HS).
What is the current status of trial NCT04988308?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2021-10-12. Estimated completion is 2022-11-23.
What interventions are being tested in trial NCT04988308?
The interventions under investigation include: Placebo (DRUG), Adalimumab (DRUG), Bermekimab (DRUG).
Who is sponsoring clinical trial NCT04988308?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.